This medicinal product contains Sorbitol and Sucrose. patients with sarcoidosis or those suffering from malignancies.
With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours (300mg/24 hours).Ĭaution is required in patients receiving treatment for cardiovascular disease (see Section 4.5 – thiazide diuretics and cardiac glycosides including digitalis).Ĭalcium Carbonate and Cholecalciferol Chewable Tablets should also be used with caution in other patients with increased risk of hypercalcaemia e.g. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria. Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully including periodic checks of plasma calcium levels and urinary calcium excretion. 4.4 Special warnings and precautions for use
0 kommentar(er)
